collection
MENU ▼
Read by QxMD icon Read
search

Radioterapia Ca Próstata

shared collection
46 papers 0 to 25 followers
https://www.readbyqxmd.com/read/27791181/targeted-molecular-genetic-imaging-and-ligand-directed-therapy-in-aggressive-variant-prostate-cancer
#1
Fortunato Ferrara, Daniela I Staquicini, Wouter H P Driessen, Sara D'Angelo, Andrey S Dobroff, Marc Barry, Lesley C Lomo, Fernanda I Staquicini, Marina Cardó-Vila, Suren Soghomonyan, Mian M Alauddin, Leo G Flores, Marco A Arap, Richard C Lauer, Paul Mathew, Eleni Efstathiou, Ana M Aparicio, Patricia Troncoso, Nora M Navone, Christopher J Logothetis, Serena Marchiò, Juri G Gelovani, Richard L Sidman, Renata Pasqualini, Wadih Arap
Aggressive variant prostate cancers (AVPC) are a clinically defined group of tumors of heterogeneous morphologies, characterized by poor patient survival and for which limited diagnostic and treatment options are currently available. We show that the cell surface 78-kDa glucose-regulated protein (GRP78), a receptor that binds to phage-display-selected ligands, such as the SNTRVAP motif, is a candidate target in AVPC. We report the presence and accessibility of this receptor in clinical specimens from index patients...
October 24, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27823821/prostate-high-dose-rate-brachytherapy-as-monotherapy-for-low-and-intermediate-risk-prostate-cancer-early-toxicity-and-quality-of-life-results-from-a-randomized-phase-ii-clinical-trial-of-one-fraction-of-19gy-or-two-fractions-of-13-5gy
#2
Gerard Morton, Hans T Chung, Merrylee McGuffin, Joelle Helou, Laura D'Alimonte, Ananth Ravi, Patrick Cheung, Ewa Szumacher, Stanley Liu, Motasem Al-Hanaqta, Liying Zhang, Alexandre Mamedov, Andrew Loblaw
BACKGROUND AND PURPOSE: Multi-fraction high dose-rate (HDR) brachytherapy as monotherapy is safe and effective for low and intermediate risk prostate cancer. Two or single fraction regimens have some radiobiological rationale. The purpose is to determine toxicity and effect on health related quality of life (HRQOL) of single fraction 19Gy or 13.5Gy×2. MATERIALS AND METHODS: Eligible patients had low or intermediate risk prostate cancer, prostate volume <60cc, and no androgen deprivation use...
November 4, 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27752756/pet-imaging-for-lymph-node-dissection-in-prostate-cancer
#3
Elena Incerti, Paola Mapelli, Luigi Gianolli, Maria Picchio
The detection of neoplastic lymph nodal involvement in prostate cancer (PCa) patients has relevant therapeutic and prognostic significance, both in the clinical settings of primary staging and restaging. Lymph nodal dissection (LND) currently represents the gold standard for evaluating the presence of lymph nodal involvement. However, this procedure is invasive, associated with morbidity, and may fail in detecting all potential lymph nodal metastatic regions. Currently the criteria for lymph nodal detection using conventional imaging techniques mainly rely on morphological assessment with unsatisfactory diagnostic accuracy...
October 17, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27859018/the-role-of-adjuvant-radiotherapy-in-pathologically-lymph-node-positive-prostate-cancer
#4
Naresh Jegadeesh, Yuan Liu, Chao Zhang, Jim Zhong, Richard J Cassidy, Theresa Gillespie, Omer Kucuk, Peter Rossi, Viraj A Master, Mehrdad Alemozaffar, Ashesh B Jani
BACKGROUND: Postoperative management of prostate cancer with lymph node involvement (LNI) is controversial. Retrospective evidence supports the selective use of radiotherapy (RT) after extended pelvic lymph node dissection. It is unclear whether this is generalizable to practice in the United States, where extended dissection is uncommon. The authors identified patients with LNI who potentially could derive a survival benefit with adjuvant RT plus androgen-deprivation therapy (ADT). METHODS: Patients with N1M0 prostate adenocarcinoma who underwent radical prostatectomy (RP) and subsequently received ADT from 2003 through 2011 were identified from the National Cancer Database...
November 8, 2016: Cancer
https://www.readbyqxmd.com/read/27864015/prediction-of-overall-survival-for-patients-with-metastatic-castration-resistant-prostate-cancer-development-of-a-prognostic-model-through-a-crowdsourced-challenge-with-open-clinical-trial-data
#5
Justin Guinney, Tao Wang, Teemu D Laajala, Kimberly Kanigel Winner, J Christopher Bare, Elias Chaibub Neto, Suleiman A Khan, Gopal Peddinti, Antti Airola, Tapio Pahikkala, Tuomas Mirtti, Thomas Yu, Brian M Bot, Liji Shen, Kald Abdallah, Thea Norman, Stephen Friend, Gustavo Stolovitzky, Howard Soule, Christopher J Sweeney, Charles J Ryan, Howard I Scher, Oliver Sartor, Yang Xie, Tero Aittokallio, Fang Liz Zhou, James C Costello
BACKGROUND: Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease...
November 15, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27863963/the-dose-response-of-salvage-radiotherapy-following-radical-prostatectomy-a-systematic-review-and-meta-analysis
#6
Christopher R King
PURPOSE/OBJECTIVES: To date neither the optimal radiotherapy dose nor the existence of a dose-response has been established for salvage RT (SRT). MATERIALS/METHODS: A systematic review from 1996 to 2015 and meta-analysis was performed to identify the pathologic, clinical and treatment factors associated with relapse-free survival (RFS) after SRT (uniformly defined as a PSA>0.2ng/mL or rising above post-SRT nadir). A sigmoidal dose-response curve was objectively fitted and a non-parametric statistical test used to determine significance...
November 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27788949/is-there-a-role-for-pelvic-irradiation-in-localized-prostate-adenocarcinoma-update-of-the-long-term-survival-results-of-the-getug-01-randomized-study
#7
Pascal Pommier, Sylvie Chabaud, Jean-Leon Lagrange, Pierre Richaud, Elisabeth Le Prise, Jean-Philippe Wagner, David Azria, Veronique Beckendorf, Jean-Philippe Suchaud, Valerie Bernier, David Perol, Christian Carrie
PURPOSE: To report the long-term results of the French Genitourinary Study Group (GETUG)-01 study in terms of event-free survival (EFS) and overall survival (OS) and assess the potential interaction between hormonotherapy and pelvic nodes irradiation. PATIENTS AND METHODS: Between December 1998 and June 2004, 446 patients with T1b-T3, N0pNx, M0 prostate carcinoma were randomly assigned to either pelvic nodes and prostate or prostate-only radiation therapy. Patients were stratified into 2 groups: "low risk" (T1-T2 and Gleason score 6 and prostate-specific antigen <3× the upper normal limit of the laboratory) (92 patients) versus "high risk" (T3 or Gleason score >6 or prostate-specific antigen >3× the upper normal limit of the laboratory)...
November 15, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27788950/androgen-deprivation-therapy-use-in-the-setting-of-high-dose-radiation-therapy-and-the-risk-of-prostate-cancer-specific-mortality-stratified-by-the-extent-of-competing-mortality
#8
Brent S Rose, Ming-Hui Chen, Jing Wu, Michelle H Braccioforte, Brian J Moran, Daniel E Doseretz, Michael J Katin, Rudolf H Ross, Sharon A Salenius, Anthony V D'Amico
PURPOSE: The addition of androgen deprivation therapy (ADT) to radiation therapy (RT) is the standard of care for men with intermediate- and high-risk prostate cancer (PC). However, whether competing mortality (CM) affects the ability of ADT to improve, survival remains unanswered. METHODS AND MATERIALS: We calculated a CM risk score using a Fine-Gray semiparametric model that included age and cardiometabolic comorbidities from a cohort of 17,669 men treated with high-dose RT with or without supplemental ADT for nonmetastatic PC...
November 15, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27745980/salvage-radiation-therapy-dose-response-for-biochemical-failure-of-prostate-cancer-after-prostatectomy-a-multi-institutional-observational-study
#9
Thomas M Pisansky, Shree Agrawal, Daniel A Hamstra, Bridget F Koontz, Stanley L Liauw, Jason A Efstathiou, Jeff M Michalski, Felix Y Feng, Matthew C Abramowitz, Alan Pollack, Mitchell S Anscher, Drew Moghanaki, Robert B Den, Kevin L Stephans, Anthony L Zietman, W Robert Lee, Michael W Kattan, Andrew J Stephenson, Rahul D Tendulkar
PURPOSE: To determine whether a dose-response relationship exists for salvage radiation therapy (RT) of biochemical failure after prostatectomy for prostate cancer. METHODS AND MATERIALS: Individual data from 1108 patients who underwent salvage RT at 10 academic centers were pooled. The cohort was enriched for selection criteria more likely associated with tumor recurrence in the prostate bed (margin positive and pre-RT prostate-specific antigen [PSA] level of ≤2...
December 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27663760/multinational-prospective-study-of-patient-reported-outcomes-after-prostate-radiation-therapy-detailed-assessment-of-rectal-bleeding
#10
Jae Y Lee, Stephanie Daignault-Newton, Gerard Heath, Sarah Scarlett, Martin G Sanda, Peter Chang, Meredith M Regan, Jeff M Michalski, Howard M Sandler, Felix Y Feng, Deborah A Kuban, Anthony L Zietman, Jay P Ciezki, Irving D Kaplan, Catrina Crociani, William P McLaughlin, Constantine A Mantz, Steven E Finkelstein, Simeng Suy, Sean P Collins, Olatz Garin, Montserrat Ferrer, Daniel A Hamstra, Daniel E Spratt
PURPOSE: The new short Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) patient-reported health-related quality of life (HRQOL) tool has removed the rectal bleeding question from the previous much longer version, EPIC-26. Herein, we assess the impact of losing the dedicated rectal bleeding question in 2 independent prospective multicenter cohorts. METHODS AND MATERIALS: In a prospective multicenter test cohort (n=865), EPIC-26 patient-reported HRQOL data were collected for 2 years after treatment from patients treated with prostate radiation therapy from 2003 to 2011...
August 3, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27602330/the-comparison-of-stereotactic-body-radiation-therapy-and-intensity-modulated-radiation-therapy-for-prostate-cancer-by-nccn-risk-groups
#11
Anthony Ricco, Genevieve Manahan, Rachelle Lanciano, Alexandra Hanlon, Jun Yang, Stephen Arrigo, John Lamond, Jing Feng, Michael Mooreville, Bruce Garber, Luther Brady
OBJECTIVES: The primary objective of this study is to compare freedom from biochemical failure (FFBF) between stereotactic body radiation therapy (SBRT) and intensity-modulated radiation therapy (IMRT) for patients with organ confined prostate cancer treated between 2007 through 2012 utilizing the 2015 National Comprehensive Cancer Network (NCCN) risk stratification guidelines. A secondary objective is to compare our updated toxicity at last follow-up compared with pretreatment with respect to bowel, bladder, sexual functioning, and need for invasive procedures between the two groups...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27171855/use-of-stereotactic-body-radiotherapy-for-prostate-cancer-in-the-united-states-from-2004-through-2012
#12
Brock R Baker, Ramsankar Basak, Jahan J Mohiuddin, Ronald C Chen
BACKGROUND: Stereotactic body radiotherapy (SBRT) is a newer treatment option for patients with localized prostate cancer. The rates of diffusion of this technology across the United States are unknown. The goal of the current study was to describe the use of SBRT among patients with prostate cancer based on different risk groups (low, intermediate, or high risk) and by type of facility (community cancer program, comprehensive community cancer program, or academic program) in which patients were treated...
July 15, 2016: Cancer
https://www.readbyqxmd.com/read/27568654/eau-estro-siog-guidelines-on-prostate-cancer-part-1-screening-diagnosis-and-local-treatment-with-curative-intent
#13
Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, Erik Briers, Marcus G Cumberbatch, Maria De Santis, Nicola Fossati, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason, Vsevolod B Matveev, Paul C Moldovan, Roderick C N van den Bergh, Thomas Van den Broeck, Henk G van der Poel, Theo H van der Kwast, Olivier Rouvière, Ivo G Schoots, Thomas Wiegel, Philip Cornford
OBJECTIVE: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence...
August 25, 2016: European Urology
https://www.readbyqxmd.com/read/26968359/hypofractionated-versus-conventionally-fractionated-radiotherapy-for-patients-with-prostate-cancer-hypro-late-toxicity-results-from-a-randomised-non-inferiority-phase-3-trial
#14
Shafak Aluwini, Floris Pos, Erik Schimmel, Stijn Krol, Peter Paul van der Toorn, Hanja de Jager, Wendimagegn Ghidey Alemayehu, Wilma Heemsbergen, Ben Heijmen, Luca Incrocci
BACKGROUND: Several studies have reported a low α to β ratio for prostate cancer, suggesting that hypofractionation could enhance the biological tumour dose without increasing genitourinary and gastrointestinal toxicity. We tested this theory in the phase 3 HYPRO trial for patients with intermediate-risk and high-risk prostate cancer. We have previously reported acute incidence of genitourinary and gastrointestinal toxicity; here we report data for late genitourinary and gastrointestinal toxicity...
April 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27635624/patient-reported-urinary-bowel-and-sexual-function-after-hypofractionated-intensity-modulated-radiation-therapy-for-prostate-cancer-results-from-a-randomized-trial
#15
Karen E Hoffman, Heath Skinner, Thomas J Pugh, Khinh R Voong, Lawrence B Levy, Seungtaek Choi, Steven J Frank, Andrew K Lee, Usama Mahmood, Sean E McGuire, Pamela J Schlembach, Weiliang Du, Jennifer Johnson, Rajat J Kudchadker, Deborah A Kuban
OBJECTIVES: Hypofractionated prostate radiotherapy may increase biologically effective dose delivered while shortening treatment duration, but information on patient-reported urinary, bowel, and sexual function after dose-escalated hypofractionated radiotherapy is limited. We report patient-reported outcomes (PROs) from a randomized trial comparing hypofractionated and conventional prostate radiotherapy. METHODS: Men with localized prostate cancer were enrolled in a trial that randomized men to either conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75...
September 15, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27681757/posttreatment-prostate-specific-antigen-6%C3%A2-months-after-radiation-with-androgen-deprivation-therapy-predicts-for-distant-metastasis-free-survival-and-prostate-cancer-specific-mortality
#16
Mihir Naik, Chandana A Reddy, Kevin L Stephans, Jay P Ciezki, Jorge Garcia, Petros Grivas, Andrew J Stephenson, Eric A Klein, Rahul D Tendulkar
OBJECTIVES/BACKGROUND: To determine whether a 6-month posttreatment prostate-specific antigen (PSA) value in patients with prostate cancer (PCa) treated with concurrent androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) serves as an early predictor for biochemical relapse free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM). METHODS: A retrospective review of intermediate-risk and high-risk PCa patients treated with EBRT and concurrent ADT at a single institution between 1996 and 2012...
November 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26792201/outcomes-of-hypofractionated-stereotactic-body-radiotherapy-boost-for-intermediate-and-high-risk-prostate-cancer
#17
Mekhail Anwar, Vivian Weinberg, Zachary Seymour, I Joe Hsu, Mack Roach, Alex R Gottschalk
BACKGROUND AND PURPOSE: Treatment of intermediate and high-risk prostate cancer with a high BED has been shown to increase recurrence free survival (RFS). While high dose rate (HDR) brachytherapy, given as a boost is effective in delivering a high BED, many patients are not candidates for the procedure or wish to avoid an invasive procedure. We evaluated the use of stereotactic body radiotherapy (SBRT) as a boost, with dosimetry modeled after HDR-boost. MATERIAL AND METHODS: Fifty patients were treated with two fractions of SBRT (9...
January 21, 2016: Radiation Oncology
https://www.readbyqxmd.com/read/26607977/a-prospective-study-of-nomogram-based-adaptation-of-prostate-radiotherapy-target-volumes
#18
Raymond Wu, Hannah Woodford, Anne Capp, Perry Hunter, Gary Cowin, Keen-Hun Tai, Paul L Nguyen, Peter Chong, Jarad Martin
BACKGROUND: A prospective clinical trial was conducted to evaluate the feasibility of a novel approach to the treatment of patients with high risk prostate cancer (HRPC) through the use of a nomogram to tailor radiotherapy target volumes. METHODS: Twenty seven subjects with HRPC were treated with a mildly hypofractionated radiotherapy regimen using image-guided IMRT technique between Jun/2013-Jan/2015. A set of validated prognostic factors were inputted into the Memorial-Sloan-Kettering Cancer Center (MSKCC) prostate cancer nomogram to estimate risk of loco-regional spread (LRS)...
November 25, 2015: Radiation Oncology
https://www.readbyqxmd.com/read/26378418/intermittent-vs-continuous-androgen-deprivation-therapy-for-prostate-cancer-a-systematic-review-and-meta-analysis
#19
REVIEW
Sindy Magnan, Ryan Zarychanski, Laurie Pilote, Laurence Bernier, Michèle Shemilt, Eric Vigneault, Vincent Fradet, Alexis F Turgeon
IMPORTANCE: Androgen deprivation is the standard therapy for patients with advanced or recurrent prostate cancer. However, this treatment causes adverse effects, alters quality of life, and may lead to castration-resistant disease. Intermittent androgen deprivation has been studied as an alternative. OBJECTIVE: To conduct a systematic review and meta-analysis comparing the efficacy and tolerability of intermittent vs continuous androgen deprivation therapy in patients with prostate cancer...
December 2015: JAMA Oncology
https://www.readbyqxmd.com/read/27591931/eau-estro-siog-guidelines-on-prostate-cancer-part-ii-treatment-of-relapsing-metastatic-and-castration-resistant-prostate-cancer
#20
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason, Henk G van der Poel, Theo H van der Kwast, Olivier Rouvière, Thomas Wiegel, Nicolas Mottet
OBJECTIVE: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature...
August 31, 2016: European Urology
label_collection
label_collection
7601
1
2
2016-09-27 03:28:20
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"